General-purpose AI was not built for regulated nuance
AI models are trained on broad, general information. They are reasonably capable at understanding straightforward business categories, but pharmaceutical manufacturing and research introduces a level of technical and regulatory nuance that general-purpose AI often gets wrong or simplifies incorrectly — the difference between WHO-GMP and US-FDA approval, between a CDMO and a pure CMO, between formulation capability and packaging capability.
When this nuance is not made explicit and unambiguous, AI models tend to default to the most well-known or most clearly-documented companies in a category, even if lesser-known companies are better qualified for a specific buyer requirement.
The opportunity this creates
Because AI struggles with pharmaceutical nuance by default, organisations that clearly and correctly explain their certifications, capabilities and specialisations have a meaningful opportunity to be understood — and recommended — ahead of larger but less clearly-documented competitors.
This is precisely the gap Emerivo's methodology is built to close: ensuring AI models correctly understand a pharmaceutical manufacturer or research organisation's real capabilities, rather than defaulting to generic or incomplete assumptions.